Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Takeda farms out cancer drug alisertib to Puma Biotech -
Puma Biotech Strikes Deal to Develop and Market its Breast Cancer Drug in China - Los Angeles Business Journal
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
PumaBiotech (@pumabiotech) / Twitter
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotech plunges on drug side effects
Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea | Business Wire